| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Compound 1541A | CTRPv2 | pan-cancer | AAC | -0.096 | 0.03 |
| mRNA | Crizotinib | CTRPv2 | pan-cancer | AAC | -0.08 | 0.03 |
| mRNA | Methotrexate | CTRPv2 | pan-cancer | AAC | 0.09 | 0.03 |
| mRNA | TKI258 | CCLE | pan-cancer | AAC | -0.13 | 0.03 |
| mRNA | Teniposide | CTRPv2 | pan-cancer | AAC | -0.097 | 0.03 |
| mRNA | TAE684 | CCLE | pan-cancer | AAC | -0.12 | 0.03 |
| mRNA | BRD-K28456706 | CTRPv2 | pan-cancer | AAC | -0.086 | 0.03 |
| mRNA | lovastatin | CTRPv2 | pan-cancer | AAC | 0.085 | 0.04 |
| mRNA | alvocidib | CTRPv2 | pan-cancer | AAC | 0.11 | 0.04 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.085 | 0.04 |